Table 1.

Incidence of myocarditis and myositis in patients receiving nivolumab monotherapy and ipilimumab and nivolumab combination therapy

Characteristic	Patients receiving nivolumab (N = 17,620)	Patients receiving nivolumab + ipilimumab (N = 2974)
Myocarditis* - no. (%)	10 (0.06%)	8 (0.27%)
Fatal events - no. (%)	1 (<0.01%)	5 (0.17%)
Myositis - no. (%)	27 (0.02%)	7 (0.24%)
Fatal events - no. (%)	2 (0.01%)	1 (0.03%)

^*Includes 6 cases of concurrent myocarditis and myositis and/or rhabdomyolysis.